While most patients with ALK- or ROS1-positive NSCLC develop resistance to tyrosine kinase inhibitor therapy, loratinib, a selective brain-penetrant ALK/ROS1 tyrosine kinase inhibitor, is active against most known resistance mutations and has been granted FDA breakthrough therapy status. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.